News

Labopharm said its response includes additional analysis of its existing data. The company suggested that it had addressed all of the matters raised by the FDA. Labopharm has

The phase II clinical trial is designed to determine the efficacy and safety of eight different dose and formulation profiles of NG2-73 compared to placebo. The primary endpoint

The study will investigate the efficacy of atacicept in patients with an inadequate response to prior treatment with TNF inhibitors. The efficacy of atacicept will be evaluated according

EPC2407 is intended for the treatment of advanced cancer patients with solid tumors that are well vascularized. These tumors include the frequently occurring cancers of the lung, gastrointestinal

The proof of concept trial is designed to evaluate the analgesic effects of TC-2696 following dental surgery. Targacept has previously conducted a phase I single ascending dose trial

The study was designed to assess the safety and efficacy of a 28-day treatment course with aztreonam lysine, as well as its ability to maintain or improve clinical

Final approval is expected upon expiry of patent protection for the brand product on June 12, 2007. Upon final approval, Lupin’s trandolapril tablets will be the AB-rated generic

The decision was made by the European Patent Office, after Ratiopharm appealed against the patent, which protected companies making cheaper generic copies of Nexium. Nexium is used in

This trial is expected to begin following completion of the current phase I/II trial. To date, Advaxis has completed enrollment and dosing of the first two of four